Therapeutic Antibody Database (TAbDab)

Explore the variable domain structures of Therapeutic Monoclonal Antibodies deposited in the PDB

 

The following table maps monoclonal antibody therapeutics to their Protein Data Bank (PDB) structures. Note that some therapeutics have been withdrawn, or are no longer in active development. Please refer to the SI of the TAP paper for original sequences and development status.

All exact and near matches to the therapeutic variable domain sequence are listed. For near matches > 98% Fv Sequence Identity, all mutations and missing PDB residues are listed (Chothia Numbering).

*mAbs labelled with an asterisk are post-Phase I therapeutics that have been identified since the TAP paper. Please cite this paper if you are making use of this database.

This page was last updated on 21st February, 2019. Many thanks to Andrew Henry of the Chemical Computing Group for submitting all structures labelled 'NEW' in light red. Please let us know if we have missed any mAb therapeutics by sending an email to opig <~at~> stats.ox.ac.uk

 
Antibody TherapeuticExact Matches (Bound/Unbound, Format, Resolution) [Additional Info]Near Matches (Bound/Unbound, Format, Resolution) [Additional Info]
Abituzumab
  • 4o02 (Bound Fab, 3.61Å)
Adalimumab
  • 6cr1 (Unbound Fab, 1.52Å) NEW
  • 4nyl (Unbound Fab, 2.80Å)
  • 3wd5 (Bound Fab, 3.10Å) [H81: Q->D]
Aducanumab
  • 6cnr (Unbound Fab, 2.09Å)
  • 6co3 (Bound Fab, 2.38Å)
Alemtuzumab
  • 1bey (Unbound Fab, 3.25Å)
  • 1ce1 (Bound Fab, 1.90Å)
Amatuximab
  • 4f33 (Unbound Fab, 1.75Å) [H1: Q->E]
  • 4f3f (Bound Fab, 2.65Å) [H1: Q-> E]
Andecaliximab
  • 5th9 (Bound Fab, 3.00Å)
Anifrolumab
  • 4qxg (Unbound Fab, 2.30Å)
Atezolizumab
  • 5xxy (Bound Fab, 2.90Å)
  • 5x8l (Bound Fab, 3.10Å)
Avelumab
  • 4nki (Unbound Fab, 2.41Å) NEW
  • 5grj (Bound Fab, 3.21Å)
Bapineuzumab
  • 4ojf (Bound Fab, 2.00Å) [H74: S->A, H77: T->S, H89: V->L, Missing H1 and L1]
  • 4hix (Bound Fab, 2.20Å) [H74: S->A, H77: T->S, H89: V->L, L1: D->Y]
  • 4onf is derived from Bapineuzumab (though many mutations away)
  • 4ong is derived from Bapineuzumab (though many mutations away)
Basiliximab
  • 1mim (Unbound Fab, 2.60Å)
  • 3iu3 (Bound Fab, 2.90Å)
Belimumab
  • 5y9k (Bound Fab, 1.90Å) NEW
  • 5y9j (Bound Fab, 2.05Å)
  • 6fxn (Bound Fab, 2.90Å)
  • 6erx (Bound Fab, 2.90Å) [H76: G->S, H100D: H->Y, H100E: A->G, H100F: L->M, H101: S->D, H102: P->V] NEW
Berlimatoxumab
  • 5k59 (Bound Fab, 2.84Å) NEW
Bevacizumab
  • 1bj1 (Bound Fab, 2.40Å) NEW
  • 6bft (Bound Fab, 2.55Å) [H28: T->D, H30: T->D, L52: S->D, L53: S->D] NEW
Bezlotoxumab
  • 4np4 (Bound Fab, 2.89Å)
Bimagrumab
  • 5nhr (Bound Fv, 3.35Å) NEW
  • 5nhw (Unbound Fab, 1.78Å) [H1: Q->E]
  • 5nh3 (Bound Fv, 2.35Å) [H1: Q->E] NEW
  • 5ngv (Bound Fv, 2.00Å) [H1: Q->E, L1: Q->E] NEW
Briakinumab
  • 5n2k (Unbound Fab, 2.22Å) [Chains BA, DC, FE, LK, NM, PO have 100% Fv SI; Chains HG and JI have H1: Q->E]
Bococizumab
  • 3sqo (Bound Fab, 2.70Å) [also 96.0% Fv SI to Ralpancizumab] NEW
Canakinumab
  • 4g5z (Unbound Fab, 1.83Å) [H42: G->A]
  • 5bvj (Unbound Fab, 2.00Å) [H1: Q->E]
  • 4g6j (Bound Fab, 2.03Å) [H42: G->A]
  • 5bvp (Bound Fab, 2.20Å) [H1: Q->E]
Carlumab
  • 4dn3 (Unbound Fab, 2.60Å) [H3: Q->E]
  • 4dn4 (Bound Fab, 2.80Å) [H3: Q->E]
Certolizumab
  • 5wuv (Unbound Fab, 1.95Å)
  • 5wux (Bound Fab, 2.90Å)
Cetuximab/Tomuzotuximab
    NB: The Fv domains of Coltuximab and Tomuzotuximab are identical except at position H113 (Cetuximab: A, Tomuzotuximab: T)

  • 5i76 (Unbound Fab, 1.92Å) [Cetuximab] NEW
  • 1yy8 (Unbound Fab, 2.00Å) [Cetuximab]
  • 5th2 (Bound Fab, 1.84Å) [Cetuximab]
  • 5f88 (Bound Fab, 2.48Å) [Cetuximab]
  • 5hyq (Bound Fab, 2.48Å) [Cetuximab]
  • 5ir1 (Bound Fab, 2.48Å) [Cetuximab]
  • 5ivz (Bound Fab, 2.48Å) [Cetuximab]
  • 5iv2 (Bound Fab, 2.48Å) [Cetuximab]
  • 5t1k (Bound Fab, 2.48Å) [Chains DC are Cetuximab; BA has H1: Q->E]
  • 5t1l (Bound Fab, 2.48Å) [Chains DC are Cetuximab; BA has H1: Q->E]
  • 6au5 (Bound Fab, 2.48Å) [Cetuximab] NEW
  • 6axp (Bound Fab, 2.48Å) [Cetuximab] NEW
  • 6ayn (Bound Fab, 2.48Å) [Cetuximab] NEW
  • 6azk (Bound Fab, 2.48Å) [Cetuximab] NEW
  • 6azl (Bound Fab, 2.48Å) [Cetuximab] NEW
  • 5id1 (Bound Fab, 2.49Å) [Cetuximab]
  • 5euk (Bound Fab, 2.50Å) [Cetuximab]
  • 5ff6 (Bound Fab, 2.50Å) [Cetuximab]
  • 5iop (Bound Fab, 2.50Å) [Cetuximab]
  • 5itf (Bound Fab, 2.51Å) [Cetuximab]
  • 5etu (Bound Fab, 2.53Å) [Cetuximab]
  • 5esq (Bound Fab, 2.55Å) [Cetuximab]
  • 5icz (Bound Fab, 2.55Å) [Cetuximab]
  • 5i2i (Bound Fab, 2.55Å) [Cetuximab]
  • 5icx (Bound Fab, 2.60Å) [Cetuximab]
  • 5hpm (Bound Fab, 2.67Å) [Cetuximab]
  • 4gw5 (Bound Fab, 2.20Å) [Cetuximab]
  • 4gw1 (Bound Fab, 2.24Å) [Cetuximab]
  • 1yy9 (Bound Fab, 2.61Å) [Cetuximab]
  • 4krp (Bound Fab, 2.82Å) [Cetuximab]
  • 4kro (Bound Fab, 3.05Å) [Cetuximab]
  • 5id0 (Bound Fab, 2.48Å) [99.55% SI to Cetuximab; H1: Q->E]
  • 5icy (Bound Fab, 2.50Å) [99.55% SI to Cetuximab; H1: Q->E]
  • 5t1m (Bound Fab, 2.53Å) [99.55% SI to Cetuximab; H1: Q->E]
  • 5gz0 (Unbound Fab, 1.70Å) [98.23% SI to Cetuximab; H15: S->G, H16: Q->G, L3: L->Q, L4: L->M] NEW
  • 6arp (Unbound Fab, 1.70Å) [98.23% SI to Cetuximab; H28: S->D, H31: N->D, L52: S->D, L56: S->D] NEW
  • 6aru (Bound Fab, 3.20Å) [98.23% SI to Cetuximab; H28: S->D, H31: N->D, L52: S->D, L56: S->D] NEW
Coltuximab/Loncastuximab
    NB: The Fv domains of Coltuximab and Loncastuximab are identical except at position L70 (Coltuximab: S, Loncastuximab: D)

  • 6ani (Bound Fab, 2.40Å) [Coltuximab]
Concizumab
  • 4dtg (Bound Fab, 1.80Å) NEW
Crenezumab
  • 5vzx (Unbound Fab, 2.50Å) NEW
  • 5vzy (Bound Fab, 2.32Å)
  • 5kmv (Unbound Fab, 2.50Å) [H108: T->L]
Daclizumab
  • 3nfs (Unbound Fab, 2.60Å)
  • 3nfp (Bound Fab, 2.86Å)
Diridavumab*
  • 3gbn (Bound Fab, 2.20Å) NEW
  • 3gbm (Bound Fab, 2.70Å) NEW
  • 5c0s (Bound Fab, 4.30Å) NEW
  • 4evn (Bound Fab, 2.85Å) [H1: Q->E, 7 Light Chain Mutations] NEW
Domagrozumab
  • 5f3h (Bound Fab, 2.70Å) [L79: Q->N] NEW
Drozitumab
  • 4od2 (Bound Fab, 3.20Å) [also 97.36% Fv SI to Lexatumumab]
Duligotuzumab
  • 3p0v (Unbound Fab, 2.85Å) [H48: V-> L, L28: N->D, L29: I->L] NEW
  • 3p0y (Bound Fab, 1.80Å) [H48: V-> L, L28: N->D, L29: I->L] NEW
  • 3p11 (Bound Fab, 3.70Å) [H48: V-> L, L28: N->D, L29: I->L] NEW
Durvalumab
  • 5xj4 (Bound scFv, 2.30Å)
  • 5x8m (Bound Fab, 2.67Å)
Eculizumab/Ravulizumab
    NB: Ravulizumab only differs from Eculizumab at H27 and H56

  • 5i5k (Bound Fab, 4.20Å) [Eculizumab]
Efalizumab
  • 3eo9 (Unbound Fab, 1.80Å)
  • 3eoa (Bound Fab, 2.80Å)
  • 3eob (Bound Fab, 3.60Å)
Elgemtumab
  • 4p59 (Bound Fab, 3.40Å) [H1: E->Q, H5: L->V, L85: T->V] NEW
Emactuzumab*
  • 4liq (Bound Fab, 2.60Å) NEW
Epratuzumab
  • 5vkk (Unbound Fab, 2.01Å) [L73: F->L]
  • 5vl3 (Bound Fab, 3.10Å) [L73: F->L] NEW
Fresolimumab
  • 3eo0 (Unbound Fab, 1.75Å)
  • 4kxz (Bound Fab, 2.83Å) NEW
  • 4kv5 (Bound scFv, 3.00Å) NEW
  • 3eo1 (Bound Fab, 3.10Å)
Fulranumab
  • 4m6o (Unbound Fab, 2.80Å) NEW
Gantenerumab
  • 5csz (Bound Fab, 1.80Å)
Gevokizumab
  • 4g6k (Unbound Fab, 1.90Å)
  • 4g6m (Bound Fab, 1.81Å)
Gedivumab
  • 4kvn (Bound Fab, 3.10Å) [H18: L->P, H27: L->P, L80: S->P, Missing L1] NEW
Golimumab
  • 5yoy (Bound Fv, 2.73Å) NEW
Guselkumab
  • 4m6m (Unbound Fab, 2.00Å)
  • 4m6n (Unbound Fab, 2.00Å)
Ibalizumab
  • 3o2d (Bound Fab, 2.19Å)
Imalumab*
  • 6foe (Unbound Fab, 2.60Å) NEW
Idarucizumab
  • 4jn2 (Unbound Fab, 1.71Å)
  • 4jn1 (Unbound Fab, 1.89Å)
Infliximab
  • 5vh3 (Unbound Fab, 2.00Å)
  • 5vh4 (Unbound Fab, 2.00Å)
  • 4g3y (Bound Fab, 2.60Å)
Ipilimumab
  • 5tru (Bound Fab, 3.00Å)
  • 5xj3 (Bound scFv, 3.20Å) NEW
Isatuximab
  • 4cmh (Bound Fab, 1.53Å)
Lampalizumab
  • 4d9q (Bound Fab, 2.28Å)
  • 4d9r (Bound Fab, 2.42Å) NEW
Lanadelumab
  • 4pub (Unbound Fab, 1.75Å)
  • 4ogy (Bound Fab, 2.10Å)
  • 4ogx (Bound Fab, 2.40Å)
Lebrikizumab
  • 4i77 (Bound Fab, 1.90Å)
Lumiliximab
  • 3fzu (Unbound Fab, 2.50Å) [H75: N->K] NEW
Lumretuzumab*
  • 4leo (Bound Fab, 2.64Å) NEW
Matuzumab
  • 3c08 (Unbound Fab, 2.15Å)
  • 5vr9 (Unbound Fab, 2.15Å) [Mutated C domains] NEW
  • 3c09 (Bound Fab, 3.20Å)
  • 5vsi (Unbound Fab, 1.51Å) [H1: Q->E] NEW
Motavizumab
  • 5k8a (Unbound Fab, 2.00Å) NEW
  • 3qwo (Bound Fab, 1.90Å)
  • 4jlr (Bound Fab, 2.71Å)
  • 3ixt (Bound Fab, 2.75Å)
  • 4zyp (Bound Fab, 5.50Å)
Muromonab
  • 1sy6 (Bound Fab, 2.10Å) [L107: K->N]
Natalizumab
  • 4irz (Bound Fab, 2.84Å) [H87: T->E]
Navivumab
  • 4r8w (Bound Fab, 2.80Å) NEW
Necitumumab
  • 6b3s (Bound Fab, 2.80Å) NEW
  • 3b2u (Bound Fab, 2.54Å)
  • 3b2v (Bound Fab, 3.30Å)
Nimotuzumab
  • 3gkw (Unbound Fab, 2.50Å)
Nivolumab
  • 5ggq (Unbound Fab, 1.90Å)
  • 5wt9 (Bound Fab, 2.40Å) NEW
  • 5ggr (Bound Fab, 3.30Å) NEW
Obinutuzumab
  • 3pp3 (Unbound Fab, 2.51Å)
  • 3pp4 (Bound Fab, 1.60Å)
Ocrelizumab
  • 4k7p (Bound Fab, 2.95Å) [Chains XY; H56: D->A, H100: N->A, L33: M->L, L92: S->A] NEW
Ofatumumab
  • 3giz (Unbound Fab, 2.20Å)
Olokizumab
  • 4cni (Bound Fab, 2.20Å)
Omalizumab
  • 4x7s (Unbound Fab, 1.90Å) [H63: L->V]
  • 2xa8 (Unbound Fab, 2.41Å) [H63: L->V]
  • 4x7t (Unbound Fab, 3.00Å) [H63: L->V]
  • 5hys (Bound Fab, 2.50Å) [H63: L->V]
  • 5g64 (Bound Fab, 3.72Å) [H63: L->V, L77: S->R, L79: Q->R]
Onartuzumab
  • 4k3j (Bound Fab, 2.80Å)
Opicinumab
  • 4oqt (Bound Fab, 3.23Å)
Palivizumab
  • 2hwz (Unbound Fab, 1.80Å) [H75: K->A, L70: E->A]
Panitumumab
  • 5sx5 (Bound Fab, 2.50Å)
  • 5sx4 (Bound Fab, 2.80Å)
Pateclizumab
  • 4mxv (Bound Fab, 3.20Å) NEW
  • 4mxv (Bound Fab, 3.60Å) NEW
Pembrolizumab
  • 5dk3 (Unbound Fc, 2.28Å)
  • 5ggs (Bound Fab, 2.00Å)
  • 5b8c (Bound Fv, 2.15Å)
  • 5jxe (Bound Fab, 2.90Å)
Pertuzumab
  • 1l7i (Unbound Fab, 1.80Å) NEW
  • 4llu (Unbound Fab, 2.16Å) [
  • 1s78 (Bound Fab, 3.25Å)
  • 4lly (Unbound Fab, 1.60Å) [H39: Q->K, H62: R->E, L38: Q->D, Missing L1]
  • 4llw (Unbound Fab, 1.95Å) [H39: Q->Y, L38: Q->R]
  • 5vsh (Unbound Fab, 2.55Å) [H39: Q->Y, H105: Q->R, L38: Q->R, L42: K->D] NEW
Pinatuzumab
  • 6and (Bound Fab, 1.75Å) [H58: N->Q]
Ponezumab
  • 3u0t (Bound Fab, 2.50Å)
Quilizumab
  • 3hr5 (Bound Fab, 2.40Å) NEW
Ramucirumab
  • 3s34 (Unbound Fab, 2.20Å)
  • 3s37 (Bound Fab 2.70Å) NEW
  • 3s36 (Bound Fab, 3.20Å)
Ranibizumab
  • 1cz8 (Bound Fab, 2.40Å)
Rituximab
  • 2osl (Bound Fab, 2.60Å)
  • 4kaq (Unbound Fab, 2.48Å) [H1: Q->E]
Rontalizumab
  • 4z5r (Bound Fab, 3.00Å)
Rozanolixizumab
  • 6fgb (Bound Fab, 2.90Å) NEW
Sifalimumab
  • 4ypg (Bound Fab, 3.00Å)
Solanezumab
  • 4xxd (Bound Fab, 2.41Å) [H55: N->S]
Suvizumab
  • 3ntc (Unbound Fab, 1.55Å) NEW
Suvratoxumab
  • 4u6v (Bound Fab, 2.56Å)
Tacatuzumab*
  • 1bfo (Unbound Fab, 2.60Å) [96.92% Fv SI; Mutations in FWH4, CDRL3/FWL4] NEW
Talocotuzumab*
  • 4jzj (Bound Fab, 2.80Å) NEW
Tanezumab
  • 4edw (Bound Fab, 2.48Å)
Tezepelumab
  • 5j13 (Bound Fab, 2.30Å)
Tralokinumab
  • 5l6y (Bound Fab, 1.99Å)
Trastuzumab/Timigutuzumab
    NB: Trastuzumab and Timigutuzumab have identical Fv Domains

  • 1fvc (Unbound Fab, 2.20Å) NEW
  • 4hkz (Bound Fab, 2.08Å)
  • 1n8z (Bound Fab, 2.52Å) NEW


  • Exact match variable domain, modified constant domain
  • 6bhz (Unbound Fab, 1.75Å) [D185A in light constant region] NEW
  • 6bi2 (Unbound Fab, 1.80Å) [D185A in light constant region; biotin conjugated] NEW
  • 6bio (Unbound Fab, 2.06Å) [N158A, D185A, K190A in light constant region] NEW


  • Exact match variable domain, but non-natural amino acids
  • 5xhg (Unbound Fab, 1.76Å) [Non-natural lysine] NEW
  • 1fve (Unbound Fab, 2.70Å) [L55: Y->E] NEW
  • 4x4x (Unbound scFv, 2.25Å) [H102: Y->V, L52: S->D] NEW
  • 6bgt (Bound Fab, 2.70Å) [H30: K->D, L52: S->D] NEW
  • 5tdo (Unbound Fab, 1.61Å) [H39: Q->K, L38: Q->E, L55: Y->E; Redesigned VH/VL interface] NEW
  • 5tdn (Unbound Fab, 1.63Å) [H39: Q->E, L38: Q->K, L55: Y->E; Redesigned VH/VL interface] NEW
  • 5tdp (Unbound Fab, 1.72Å) [H39: Q->E, L38: Q->K, L55: Y->E; Redesigned VH/VL interface] NEW
  • 4x4y (Unbound scFv, 2.49Å) [H30: K->D, H102: Y->V, L52: S->D] NEW
  • 1fvd (Unbound Fab, 2.50Å) [H78: A->L, H102: Y->V, L55: Y->E] NEW
  • 3be1 (Bound Bispecific Fab, 2.90Å) [96.47% Fv SI, Bispecific] NEW
  • 3bdy (Bound Bispecific Fab, 2.60Å) [96.47% Fv SI, Bispecific] NEW
  • 5u6a (Bound Fab, 1.74Å) [94.27% Fv SI, Engineered to bind Meditope] NEW
  • 5u3d (Bound Fab, 1.77Å) [94.27% Fv SI, Engineered to bind Meditope] NEW
  • 5u5f (Bound Fab, 1.81Å) [94.27% Fv SI, Engineered to bind Meditope] NEW
  • 6b9z (Unbound Fab, 1.82Å) [94.27% Fv SI, Engineered to bind Meditope] NEW
  • 5u5m (Bound Fab, 1.88Å) [94.27% Fv SI, Engineered to bind Meditope] NEW
  • 6bah (Bound Fab, 1.90Å) [94.27% Fv SI, Engineered to bind Meditope] NEW
  • 4ioi (Bound Fab, 1.95Å) [94.27% Fv SI, Engineered to bind Meditope]
  • 4hjg (Bound Fab, 2.00Å) [94.27% Fv SI, Engineered to bind Meditope]
  • 6bae (Bound Fab, 2.14Å) [94.27% Fv SI, Engineered to bind Meditope] NEW
  • 6b9y (Bound Fab, 2.14Å) [94.27% Fv SI, Engineered to bind Meditope] NEW
Tremelimumab
  • 5ggu (Bound Fab, 2.29Å) NEW
  • 5ggv (Bound Fab, 2.00Å)
Utomilumab
  • 6a3w (Bound Fv, 2.00Å) NEW
  • 6mi2 (Bound Fab, 2.72Å) NEW
Urelumab
  • 6mhr (Bound Fab, 2.80Å) NEW
Ustekinumab
  • 3hmw (Unbound Fab, 3.00Å)
  • 3hmx (Bound Fab, 3.00Å)
Vesencumab
  • 2qqn (Bound Fab, 2.20Å) NEW
Zenocutuzumab*
  • 5o4o (Bound Fab, 3.40Å) NEW
  • 5o7p (Bound Fab, 4.50Å) NEW